
Opinion|Videos|December 23, 2024
Early Intervention and Personalized Frontline Therapies in Multiple Myeloma
Author(s)Shaji Kumar, MD
A panelist discusses how clinicians are navigating the evolving landscape of multiple myeloma treatment, from considering early intervention in high-risk smoldering cases to personalizing initial therapy choices between triplet and quadruplet regimens.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How are you approaching patients with high-risk smoldering multiple myeloma, particularly in considering early intervention before traditional CRAB (hypercalcemia, renal dysfunction, anemia, bone disease) criteria are met?
- What is your approach to personalizing first-line therapy selection among VRd (bortezomib, lenalidomide, and dexamethasone), KRd (carfilzomib, lenalidomide, and dexamethasone), and Dara-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone), considering the emerging quadruplet regimens?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
NIH Grant Terminations Disrupt 1 in 30 Clinical Trials, Impacting Over 74,000 Participants
2
How Effective and Safe Are GLP-1s for Weight Loss?
3
Rescue Therapy With Rozanolixizumab Promising in Triple-Seronegative MG
4
FDA Approves Plozasiran to Reduce Triglycerides in Familial Chylomicronemia Syndrome
5
















































